Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Phase 2 Terminated 20 enrolled University Health Network, Toronto Multiple Myeloma Research Consortium · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 2 study to see how effective investigational drug, JNJ-42756493, is when given in combination with dexamethasone in two groups of patients with multiple myeloma (cancer of the plasma cells, a type of white blood cell present in bone marrow) that has relapsed (has come back after a period of improvement) or refractory (did not respond to standard treatment).

Timeline

Start: 2017-06-13
Primary completion: 2018-11-13
Completion: 2018-11-13

Publications

Croucher DC, Devasia AJ, Abelman DD, Mahdipour-Shirayeh A, Li Z, Erdmann N, Tiedemann R, Pugh TJ, Trudel S. Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression. Cold Spring Harb Mol Case Stud. 2023 May 9;9(2):a006249. doi: 10.1101/mcs.a006249. Print 2023 Apr.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erdafitinib	Small molecule	9 mg	Oral
Background	Dexamethasone	Small molecule	20 mg	Oral
Background	Dexamethasone	Small molecule	40 mg	Oral

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Summary

Timeline

Publications

Drugs

Indications